Bioavailability Study of Candesartan Cilexetil 8mg Tablet Under Fasting Conditions
Status:
Completed
Trial end date:
2014-01-22
Target enrollment:
Participant gender:
Summary
This will be an open-label, randomized, single dose, two-way crossover study. Each subject
will participate in both treatment periods and will receive single oral doses of candesartan
cilexetil (GW615775) and reference candesartan cilexetil (ATACAND™); the treatment periods
will be separated by a washout period of at least 7 days and no greater than 14 days. This
study aims to determine the relative bioavailability of an 8mg test formulation tablet of
candesartan cilexetil (GW615775) compared to an 8mg reference tablet of candesartan cilexetil
in healthy adult subjects. ATACAND is a registered trademark of the AstraZeneca group of
companies.